These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 19480873

  • 1. Driving behaviors among community-dwelling persons with multiple sclerosis.
    Schultheis MT, Weisser V, Manning K, Blasco A, Ang J.
    Arch Phys Med Rehabil; 2009 Jun; 90(6):975-81. PubMed ID: 19480873
    [Abstract] [Full Text] [Related]

  • 2. Examining the relationship between cognition and driving performance in multiple sclerosis.
    Schultheis MT, Weisser V, Ang J, Elovic E, Nead R, Sestito N, Fleksher C, Millis SR.
    Arch Phys Med Rehabil; 2010 Mar; 91(3):465-73. PubMed ID: 20298841
    [Abstract] [Full Text] [Related]

  • 3. Vision and driving in multiple sclerosis.
    Schultheis MT, Manning K, Weisser V, Blasco A, Ang J, Wilkinson ME.
    Arch Phys Med Rehabil; 2010 Feb; 91(2):315-7. PubMed ID: 20159138
    [Abstract] [Full Text] [Related]

  • 4. Actual reality: a new approach to functional assessment in persons with multiple sclerosis.
    Goverover Y, O'Brien AR, Moore NB, DeLuca J.
    Arch Phys Med Rehabil; 2010 Feb; 91(2):252-60. PubMed ID: 20159130
    [Abstract] [Full Text] [Related]

  • 5. The relation between subjective and objective measures of everyday life activities in persons with multiple sclerosis.
    Goverover Y, Kalmar J, Gaudino-Goering E, Shawaryn M, Moore NB, Halper J, DeLuca J.
    Arch Phys Med Rehabil; 2005 Dec; 86(12):2303-8. PubMed ID: 16344027
    [Abstract] [Full Text] [Related]

  • 6. Impact of an educational program on the safety of high-risk, visually impaired, older drivers.
    Owsley C, McGwin G, Phillips JM, McNeal SF, Stalvey BT.
    Am J Prev Med; 2004 Apr; 26(3):222-9. PubMed ID: 15026102
    [Abstract] [Full Text] [Related]

  • 7. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
    Ostberg A, Pittas F, Taylor B.
    Intern Med J; 2005 Jul; 35(7):382-7. PubMed ID: 15958106
    [Abstract] [Full Text] [Related]

  • 8. Illness and demographic correlates of chronic pain among a community-based sample of people with multiple sclerosis.
    Douglas C, Wollin JA, Windsor C.
    Arch Phys Med Rehabil; 2008 Oct; 89(10):1923-32. PubMed ID: 18929020
    [Abstract] [Full Text] [Related]

  • 9. Randomized control trial of effects of a 10-week inspiratory muscle training program on measures of pulmonary function in persons with multiple sclerosis.
    Fry DK, Pfalzer LA, Chokshi AR, Wagner MT, Jackson ES.
    J Neurol Phys Ther; 2007 Dec; 31(4):162-72. PubMed ID: 18172412
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of an energy conservation course for persons with multiple sclerosis.
    Mathiowetz V, Matuska KM, Murphy ME.
    Arch Phys Med Rehabil; 2001 Apr; 82(4):449-56. PubMed ID: 11295003
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Use of goal attainment scaling in inpatient rehabilitation for persons with multiple sclerosis.
    Khan F, Pallant JF, Turner-Stokes L.
    Arch Phys Med Rehabil; 2008 Apr; 89(4):652-9. PubMed ID: 18373995
    [Abstract] [Full Text] [Related]

  • 14. [Determination of CSF guanase activity in multiple sclerosis: a comparative study on various parameters to monitor the disease activity].
    Kaneshige Y, Matsumoto H, Chiba S, Hashimoto S, Noro H.
    Rinsho Shinkeigaku; 1989 Jul; 29(7):854-8. PubMed ID: 2805507
    [Abstract] [Full Text] [Related]

  • 15. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
    Markianos M, Koutsis G, Evangelopoulos ME, Mandellos D, Karahalios G, Sfagos C.
    J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The development and validation of the impact of multiple sclerosis scale and the symptoms of multiple sclerosis scale.
    McMillan L, Moore KA.
    Arch Phys Med Rehabil; 2006 Jun; 87(6):832-41. PubMed ID: 16731220
    [Abstract] [Full Text] [Related]

  • 18. Tried and tested: the psychometric properties of the multiple sclerosis impact scale (MSIS-29) in a population-based study.
    Gray O, McDonnell G, Hawkins S.
    Mult Scler; 2009 Jan; 15(1):75-80. PubMed ID: 18829636
    [Abstract] [Full Text] [Related]

  • 19. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, Uitdehaag BM.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.